2,2'-((1R,3R,4S)-4-methyl-4-vinylcyclohexane-1,3-diyl) bis(prop-2-en-1-amine), a bisamino derivative of β-Elemene, inhibits glioblastoma growth through downregulation of YAP signaling

• Published in: American journal of cancer research Vol. 12; no. 12; pp. 5484 - 5499
• Main Authors: Cao, Li-Ying, Xu, Jia-Yun, Zhuo, Xiao-Tao, Zhang, Wei, Wei, Li-Jia, Dong, Jian-Hong, Bai, Ren-Ren, Wang, Xin, Jiang, Yuan-Yuan, Wang, Yong-Jie, Ye, Xiang-Yang, Xie, Tian, Huang, Zhi-Hui
• Format: Journal Article
• Language: English
• Published: United States e-Century Publishing Corporation 2022
• Subjects: Original; β-Elemene; migration; YAP; derivative; glioblastoma; proliferation
• ISSN: 2156-6976; 2156-6976

β-Elemene, a compound extracted from Chinese herb , has been demonstrated with antitumor effects in various cancers, including glioblastoma (GBM), a primary brain tumor with high morbidity and mortality. In this study, we reported a bisamino derivative of β-Elemene, 2, 2'-((1R, 3R, 4S)-4-methyl-4-vinylcyclohexane-1, 3-diyl) bis(prop-2-en-1-amine) (compound 1), displayed a better anti-GBM effect than β-Elemene with lower concentration. GBM cell lines (C6 and U87) were treated with compound 1 and subsequently analyzed by several assays. Compound 1 significantly inhibited the migration of C6 and U87 cells based on wound healing assay, transwell assay and inverted migration assay. Furthermore, colony formation assay, immunostaining and flow cytometry assays revealed that compound 1 significantly inhibited the proliferation of GBM cells. In addition, compound 1 induced the apoptosis of GBM cells. Mechanistically, we found Yes-associated protein (YAP) was down-regulated in compound 1-treated GBM cells, and the overexpression of YAP partially rescued the anti-GBM effects of compound 1. Finally, compound 1 suppresses the GBM growth in xenograft model through inactivation YAP signaling. Taken together, these results reveal that a novel derivative of β-Elemene, compound 1, exhibits more potent anti-GBM activity than β-Elemene through inactivating YAP signaling pathway, which will provide novel strategies for the treatment of GBM.